Siemens Healthineers has initiated a formal carve-out of its diagnostics unit, rebranding the business as Olyrian Diagnostics ahead of a planned divestment by mid-2028. Simultaneously, the parent company plans to drop 'Siemens' from its name as Siemens AG prepares to spin off a 30% stake. While facing short-term stranded costs, the diagnostics business targets €400 million in savings to boost its 5.4% fourth-quarter margin to mid-teens over the medium term.
Diagnostics Carve-Out plans and rebranding
- ▪Siemens Healthineers expects the carve-out separation process for its diagnostics business to be completed by mid-2028
- ▪Siemens Healthineers announced on November 5, 2026 that it has begun carving out its in vitro diagnostics business into a standalone entity
- ▪Siemens Healthineers previously indicated that its diagnostics separation could take around two years and that the diagnostics business might fully exit the Siemens Healthineers group by 2030
Diagnostics financial metrics and targets
- ▪Siemens Healthineers CFO Jochen Schmitz stated on November 5, 2026 that the diagnostics unit aims to achieve mid-teens adjusted EBIT margins over the medium term
- ▪The diagnostics business accounts for approximately 20% of Siemens Healthineers' workforce, generates 17% of total revenue, and produces over 16 billion diagnostic tests annually
- ▪Siemens Healthineers' diagnostics business reported an adjusted EBIT margin of 5.4% in the fourth quarter and is targeting an additional €400 million ($450 million) in cost savings
Parent group spin-off and corporate rebranding
- ▪In 2025, Siemens laid out plans to deconsolidate Siemens Healthineers by spinning off a 30% stake to shareholders
- ▪Siemens Healthineers plans to rebrand itself as Healthineers by dropping Siemens from its corporate name as it advances toward a spin-off from parent group Siemens
Story comments
Loading comments…